Latest News and Press Releases

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single...

LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The following is a statement by Renovaro (Nasdaq: RENB) in response to Hindenburg's recent opinion piece: We felt compelled to comment on the shorter...

A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.Expected breakthroughs by combining technologies in (early) cancer detection and recurrence of cancer with a single...

LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB) announced today that it completed its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew,...

LOS ANGELES, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB) (the “Company”), a biotechnology corporation focusing on cell, gene, and immunotherapy, announced today the...

LOS ANGELES, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, Happy New Year. I write to update you on our key developments towards precision medicine...

LOS ANGELES, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), a biotechnology corporation focusing on cell, gene, and immunotherapy, has announced that Avram...

LOS ANGELES, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (NASDAQ: RENB)(Renovaro), an advanced, pre-clinical biotechnology firm in cell, gene, and immunotherapy focused on solid...

LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide you with an update on our recent news of signing a definitive...

Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide...